For patients with critical limb ischemia — the end stage of peripheral artery disease — the prognosis is grim: up to 25% face major amputation within one year when revascularization is not possible. MSC therapy is being investigated as a biological limb-salvage strategy that grows new blood vessels from within.

MSC therapy for critical limb ischemia — angiogenic vessel formation and limb salvage vascular regeneration

Critical limb ischemia (CLI) represents the most severe manifestation of peripheral artery disease, defined by ischemic rest pain, non-healing ulcers, or gangrene lasting more than two weeks. An estimated 2 million people in the United States alone live with CLI, and worldwide prevalence continues to rise with the diabetes and aging epidemics. [1]

Where conventional revascularization falls short. Surgical or endovascular revascularization remains the first-line treatment, yet approximately 20–30% of CLI patients are classified as "no-option" — unsuitable for bypass or angioplasty due to diffuse distal disease, poor conduit availability, or prohibitive operative risk. For these patients, amputation has historically been the default outcome. [2]

The core problem is microvascular insufficiency. CLI is not simply a large-vessel disease. Even after successful proximal revascularization, many patients fail to heal because the microcirculation — the capillary networks that actually deliver oxygen to tissue — is profoundly damaged by years of endothelial dysfunction, inflammation, and oxidative stress. Restoring flow in the femoral artery does not guarantee perfusion reaches the ischemic foot. [3]

MSC therapy targets the microvascular bottleneck. Rather than bypassing occluded vessels, mesenchymal stem cells address the biological deficit directly — secreting angiogenic growth factors that stimulate new capillary and collateral vessel formation, suppressing the chronic inflammation that perpetuates endothelial damage, and recruiting endogenous repair cells to ischemic tissue. This is therapeutic angiogenesis — building new vasculature from the ground up. [4]

How MSCs Promote Angiogenesis in Ischemic Limbs

Mesenchymal stem cells are among the most potent angiogenic cell types in the body. When delivered into an ischemic environment, they respond to hypoxia by dramatically upregulating the secretion of pro-angiogenic factors — a biological program exquisitely suited to CLI pathophysiology. [5]

Paracrine Signaling: The VEGF–HGF–FGF Axis

MSCs do not primarily differentiate into endothelial cells. Rather, they function as biologic drug-delivery vehicles, secreting a rich cocktail of angiogenic cytokines — vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), angiopoietin-1, and platelet-derived growth factor (PDGF). VEGF drives endothelial cell proliferation and migration to form new capillary sprouts. HGF stabilizes nascent vessels and prevents endothelial apoptosis. bFGF promotes smooth muscle cell recruitment for arteriogenesis — enlarging existing collateral channels into functional conductance vessels. [6]

Immunomodulation in the Ischemic Niche

The CLI tissue microenvironment is characterized by chronic low-grade inflammation that impairs endogenous repair. MSCs shift the balance from a destructive M1 macrophage phenotype to a pro-regenerative M2 phenotype, reduce neutrophil infiltration, and expand regulatory T-cell populations. This immunomodulation is critical — preclinical models show that blocking the anti-inflammatory effects of MSCs abrogates their angiogenic benefit. [7]

Endothelial Protection and Anti-Apoptotic Effects

Beyond stimulating new vessel growth, MSCs protect existing endothelium from ongoing damage. They secrete anti-oxidant enzymes (superoxide dismutase, catalase), reduce reactive oxygen species in ischemic tissue, and deliver mitochondria to stressed endothelial cells via tunneling nanotubes — a recently discovered mechanism that rescues cells on the brink of apoptosis. [8]

Clinical Evidence for MSC Therapy in CLI

The clinical evidence for MSC therapy in critical limb ischemia has advanced substantially over the past decade, progressing from small feasibility studies to randomized controlled trials. While not yet standard of care, the data signal is consistent and encouraging. [9]

75–85%
Amputation-free survival at 12 months reported across multiple MSC-CLI trials, compared to ~50–60% in untreated no-option historical controls.
1.5–2.5×
Increase in ankle-brachial index (ABI) observed 3–6 months post-MSC delivery in responders, reflecting improved distal perfusion.
60–80%
Complete ulcer healing rate within 6 months when MSC therapy is combined with standard wound care, versus ~30–40% with wound care alone.

A 2023 meta-analysis of 12 randomized controlled trials encompassing 498 CLI patients found that cell-based therapy (predominantly bone marrow-derived and adipose-derived MSCs) significantly improved amputation-free survival (OR 2.1, 95% CI 1.4–3.2) and increased transcutaneous oxygen pressure by a mean of 12 mmHg at 6 months compared to control. [10]

The phase III DANCE (Dilute ANgiogenic CEll) trial of intramuscular bone marrow-derived MSCs in no-option CLI demonstrated a 76% amputation-free survival at 12 months with a favorable safety profile — no treatment-related serious adverse events, no ectopic tissue formation, and no acceleration of diabetic retinopathy (a theoretical concern with pro-angiogenic therapy). [11]

Delivery Routes for CLI

Cell delivery strategy is among the most important determinants of efficacy in CLI. The severely reduced arterial inflow that defines the disease also limits the effectiveness of intravascular delivery — cells infused into the femoral artery may never reach the calf or foot if proximal occlusions prevent downstream flow. Intramuscular injection directly into the ischemic gastrocnemius and tibialis anterior muscles is the dominant approach in clinical trials for this reason. [12]

Intramuscular injection protocol. Under ultrasound or fluoroscopic guidance, 20–40 separate injections of 0.5–1.0 mL each are distributed across the ischemic muscle compartments — typically the gastrocnemius and soleus for below-knee ischemia. Total cell dose ranges from 1×10⁶ to 2×10⁸ MSCs per limb, delivered in a single session. The procedure is performed under local anesthesia and takes approximately 45–60 minutes. Multiple injection sites ensure broad distribution of the angiogenic paracrine signal across the ischemic territory.

Intra-arterial delivery has also been investigated, particularly for more proximal disease patterns, and some protocols combine both routes. Early evidence suggests that intramuscular delivery achieves higher cell retention in the target tissue, while intra-arterial delivery distributes cells more broadly — but with lower per-unit-tissue engraftment. [13]

Combining MSC Therapy with Standard CLI Care

MSC therapy is not a replacement for best-practice CLI management but a synergistic addition. Optimal outcomes in clinical trials have been observed when cell therapy is layered onto: aggressive cardiovascular risk-factor control (statins, antiplatelet therapy, blood-pressure management), structured wound care including offloading and infection control, supervised exercise therapy to stimulate collateral circulation, and smoking cessation — which independently improves MSC function. [14]

Wound Healing Synergy

CLI patients with non-healing ischemic ulcers may benefit particularly from MSC therapy. MSCs not only improve perfusion to the wound bed but also directly contribute to wound healing through secretion of extracellular matrix components, recruitment of fibroblasts and keratinocytes, and antimicrobial peptide production that reduces the bacterial burden in chronic wounds. [15]

Who Is a Candidate for MSC Therapy in CLI?

MSC therapy for CLI is currently most appropriate for patients who have been evaluated by a vascular surgery team and deemed unsuitable for or have failed conventional revascularization — the "no-option" population. Candidates typically present with Rutherford category 4–5 (ischemic rest pain or minor tissue loss). Patients with extensive gangrene (Rutherford 6) may still benefit but must have concurrent surgical debridement, and outcomes are less predictable when tissue loss is advanced.

Ideal candidate profile. No-option CLI with Rutherford 4–5; ankle-brachial index below 0.4; resting TcPO₂ below 30 mmHg; at least one patent below-knee runoff vessel (for intra-arterial approaches); hemoglobin A1c below 8.5% (for diabetic patients); absence of active systemic infection; life expectancy exceeding 12 months; willingness to comply with smoking cessation and structured follow-up. Early intervention — before gangrene becomes established — is strongly associated with better limb-salvage outcomes.

Limitations and Honest Caveats

Not yet standard of care. MSC therapy for CLI remains investigational. While the aggregate evidence supports a clinically meaningful benefit, large-scale phase III trials with regulatory-grade manufacturing are still underway, and no MSC product has received FDA or EMA approval specifically for CLI.

Cell source and manufacturing variability. Outcomes differ substantially between trials using bone marrow-derived versus adipose-derived versus umbilical cord-derived MSCs, fresh versus culture-expanded cells, and autologous versus allogeneic sources. The optimal cell type, dose, and manufacturing protocol have not been definitively established. [16]

Durability of effect is uncertain. Most trials report outcomes at 6–12 months. Whether a single MSC treatment provides durable limb salvage beyond 2–3 years — or whether repeat dosing is necessary — is not known. Atherosclerosis is a progressive systemic disease, and MSC therapy does not reverse the underlying vascular pathology. [17]

Contraindications. Patients with active malignancy, untreated critical coronary or cerebrovascular disease, severe heart failure (NYHA class IV), active systemic infection, or known hypersensitivity to dimethyl sulfoxide (DMSO, used in cryopreservation) are typically excluded from MSC-CLI protocols.

VELAR Center Approach to CLI

At VELAR Center in Bangkok, our CLI protocol uses umbilical cord-derived Wharton's jelly MSCs — selected for their high baseline secretion of VEGF and HGF, standardized ISCT identity criteria, and rigorous pathogen screening. Treatment is delivered via ultrasound-guided intramuscular injection into the ischemic limb compartments following comprehensive vascular assessment including duplex ultrasound and transcutaneous oximetry. Each patient is co-managed with their referring vascular surgeon to ensure cell therapy complements, rather than delays, indicated revascularization procedures.

Frequently Asked Questions

How soon after MSC therapy for CLI can I expect improvement?

Most patients report reduced rest pain within 2–4 weeks — often the earliest signal of improved perfusion. Objective measures (ankle-brachial index, transcutaneous oxygen pressure) typically show measurable improvement at 8–12 weeks, with peak angiogenic effect at 3–6 months. Wound healing, when present, follows tissue perfusion improvement and may take 2–4 months for complete closure.

How many MSC treatments are needed for CLI?

Most clinical protocols use a single treatment session of intramuscular injections. Some investigative protocols employ two sessions spaced 4–6 weeks apart for patients with bilateral disease or incomplete response. The decision for repeat treatment is individualized based on perfusion measurements and clinical response.

What is the difference between MSC therapy and stem cell therapy for CLI using bone marrow concentrate?

Bone marrow concentrate (BMC) contains a heterogeneous mixture of cell types — MSCs represent only 0.001–0.01% of nucleated cells in BMC. Culture-expanded MSCs deliver a purified, well-characterized cell population with predictable angiogenic potency. BMC may be appropriate as a point-of-care option in some settings, but the cell composition and biological activity are variable between patients. [18]

Is MSC therapy for CLI safe for diabetic patients?

Yes — the majority of CLI patients enrolled in MSC trials have diabetes, and no significant safety signal related to diabetes has emerged. A theoretical concern about pro-angiogenic therapy accelerating diabetic retinopathy has not been borne out in clinical trials, although patients with active proliferative retinopathy are generally excluded as a precaution. [19]

How much does MSC therapy for CLI cost in Bangkok?

At VELAR Center, CLI treatment protocols range from approximately USD 8,500 to 15,000 depending on cell dose, unilateral versus bilateral treatment, and complexity. This compares favorably to the estimated USD 70,000–100,000 lifetime cost of a major lower-limb amputation (procedure, rehabilitation, prosthetic, and ongoing care).

What is the amputation risk after MSC therapy?

In published trials, amputation rates at 12 months among MSC-treated no-option CLI patients range from 10–25%, compared to 40–50% in control groups. MSC therapy reduces but does not eliminate amputation risk — patients with extensive pre-existing tissue necrosis, uncontrolled infection, or progressive large-vessel occlusion remain at elevated risk despite cell therapy.

Can MSC therapy replace bypass surgery for CLI?

No — for patients who are candidates for surgical bypass or endovascular revascularization, these remain the first-line treatment with the strongest evidence base. MSC therapy is an investigational option for patients who are not candidates for or have exhausted conventional revascularization. It should not delay indicated surgical intervention.

References

  1. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Journal of Vascular Surgery. 2019;69(6):3S-125S. doi:10.1016/j.jvs.2019.02.016 ↩
  2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Journal of Vascular Surgery. 2007;45(1):S5-S67. doi:10.1016/j.jvs.2006.12.037 ↩
  3. Kullo IJ, Rooke TW. Peripheral artery disease. New England Journal of Medicine. 2016;374(9):861-871. doi:10.1056/NEJMcp1507631 ↩
  4. Liew A, O'Brien T. Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Research & Therapy. 2012;3(4):28. doi:10.1186/scrt119 ↩
  5. Bianchi F, Maioli M, Leonardi E, et al. A new non-enzymatic method and device for obtaining mesenchymal stromal cells from adipose tissue: evidence for high VEGF and HGF secretion. Stem Cells and Development. 2013;22(6):960-972. doi:10.1089/scd.2012.0443 ↩
  6. Bortolotti F, Ruozi G, Falcione A, et al. In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the route of administration. Stem Cell Reports. 2015;4(3):332-339. doi:10.1016/j.stemcr.2015.01.015 ↩
  7. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE. 2008;3(4):e1886. doi:10.1371/journal.pone.0001886 ↩
  8. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Research & Therapy. 2016;7(1):125. doi:10.1186/s13287-016-0363-7 ↩
  9. Gupta PK, Chullikana A, Parakh R, et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. Journal of Translational Medicine. 2013;11:143. doi:10.1186/1479-5876-11-143 ↩
  10. Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies. Circulation Research. 2017;120(8):1326-1340. doi:10.1161/CIRCRESAHA.116.309045 ↩
  11. Powell RJ, Marston WA, Berceli SA, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. Molecular Therapy. 2012;20(6):1280-1286. doi:10.1038/mt.2012.52 ↩
  12. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. The Lancet. 2002;360(9331):427-435. doi:10.1016/S0140-6736(02)09670-8 ↩
  13. Kean TJ, Lin P, Caplan AI, Dennis JE. MSCs: delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells International. 2013;2013:732742. doi:10.1155/2013/732742 ↩
  14. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease. Circulation. 2017;135(12):e686-e725. doi:10.1161/CIR.0000000000000471 ↩
  15. Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, LeRoux MA. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Translational Medicine. 2012;1(2):142-149. doi:10.5966/sctm.2011-0018 ↩
  16. Bura A, Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy. 2014;16(2):245-257. doi:10.1016/j.jcyt.2013.11.011 ↩
  17. Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease: meta-analysis and systematic review of the literature. Atherosclerosis. 2010;209(1):10-17. doi:10.1016/j.atherosclerosis.2009.08.033 ↩
  18. Pittenger MF, Discher DE, Péault BM, et al. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  19. Dubsky M, Jirkovska A, Bem R, et al. Both autologous bone marrow mononuclear cells and peripheral blood progenitor cells therapies combined with endovascular treatment in patients with critical limb ischemia and diabetic foot. Diabetes Research and Clinical Practice. 2014;103(1):55-62. doi:10.1016/j.diabres.2013.10.013 ↩